ASCO 2025 ProstACT Global, phase 3 study of 177Lu-rosptamab + standard of care versus standard of care alone, metastatic castration-resistant prostate cancer (mCRPC).

Mario Fernández, MD, Melanie Pepin, MS, CGC, and Kristen Watts The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, was host to the Breakout Session: Tracking and Tackling an ...

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic ...

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025, prostate cancer, radioligand therapy (RLT), Radioligand Therapies in Prostate Cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), 177Lu-PSMA-617.

ASCO 2025 BULLSEYE trial, Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy, androgen deprivation therapy (ADT), 177Lu-PSMA-617, PSMAddition.

SNMMI 2025, PROSTATE CANCER, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Artificial Intelligence-based Risk Score for Prostate Cancer on PSMA PET/CT.

ASCO GU 2025, metastatic castration resistant prostate cancer (mCRPC), Precision Diagnostics in Prostate Cancer Treatment (PREDICT): PREDICT trial, Alliance A032102, H3 lysine 27 methylation (H3K27me) ...

AUA 2025, penile fracture, AUA Guidelines for penile fractures, intralesional Collagenase Clostridium Histolyticum therapy (CCH), Peyronie’s Disease (PD), IMPRESS Trials.